Peptides: BPC-157 — Complete Overview
BPC-157 (sequence GEPPPGKPADDAGLV) activates nitric oxide synthase, upregulates VEGF, and modulates EGF-R and PDGFR-β in animal models. 10mcg/kg dose used in most rat studies. No human RCTs completed.
| Measure | Value | Unit | Notes |
|---|---|---|---|
| Evidence Grade | C | grade | Animal grade — almost exclusively animal data; no completed human RCTs as of 2026; extensive rat studies from Sikiric lab |
| Amino Acid Sequence | GEPPPGKPADDAGLV | sequence | 15 amino acids; derived from a protein in human gastric juice; stable in gastric acid (unusual for peptides) |
| Primary Animal Dose | 10 | mcg/kg | Standard dose in rat studies; rough human equivalent ~162mcg for 70kg person by body weight (interspecies scaling imprecise) |
| Human Equivalent Estimate | ~162 | mcg | Body-weight scaled estimate for 70kg human from 10mcg/kg rat dose; interspecies translation is uncertain |
| Mechanism #1 | NO synthase activation | pathway | Activates nitric oxide (NO) synthase pathway, increasing local blood flow to injured tissue |
| Mechanism #2 | VEGF upregulation | pathway | Upregulates vascular endothelial growth factor, promoting angiogenesis into avascular tissue (tendons, cartilage) |
| Receptor Type | Not hormone receptor | classification | BPC-157 does NOT bind androgen receptor or GH receptor — it is neither a steroid nor a growth hormone secretagogue |
BPC-157 is the most widely discussed healing peptide in the performance and recovery communities. It has an unusual combination of: (1) extensive animal research from a credible academic institution, (2) plausible and well-characterized mechanisms, and (3) zero completed human clinical trials. Understanding this profile precisely — not overstating it, not dismissing it — is the purpose of this page.
What BPC-157 Is
BPC-157 stands for Body Protection Compound 157. It is a synthetic pentadecapeptide (15 amino acids) with the sequence GEPPPGKPADDAGLV. It was originally isolated and characterized from a protein in human gastric juice, which is why it is sometimes called a “gastric peptide.” It is not a hormone, not a steroid, and does not interact with androgen or growth hormone receptors.
One unusual property: BPC-157 is stable in gastric acid, which is atypical for peptides. Most peptides are degraded rapidly in the stomach. This property is why oral administration is considered a plausible route — though oral bioavailability in humans remains uncharacterized.
Mechanisms (All from Animal Studies)
BPC-157’s biological activity is mediated through several distinct pathways:
- Nitric oxide (NO) synthase activation: Increases local production of nitric oxide, a vasodilator, improving blood flow to injured or ischemic tissue
- VEGF upregulation: Stimulates vascular endothelial growth factor expression, promoting angiogenesis — the formation of new blood vessels into avascular tissue like tendons and cartilage
- Growth factor receptor modulation: Modulates EGF receptor (EGFR) and PDGF receptor β (PDGFR-β), influencing cell proliferation and tissue repair signaling
- Neurotransmitter modulation: Modulates GABAergic and dopaminergic pathways in the CNS — relevant to the neuroprotection research in rat models
Evidence Summary
| Study Area | Model | Key Finding | Dose Used | Evidence Level |
|---|---|---|---|---|
| Tendon healing | Rat Achilles transection (animal study) | Accelerated tensile strength recovery; faster vascularization | 10mcg/kg | C — animal only |
| Gut healing / ulcer | Rat gastric ulcer models (animal study) | Significant healing vs control at 24h; stable in gastric acid | 10mcg/kg oral/IP | C — animal only |
| CNS / neuroprotection | Rat brain injury models (animal study) | Reduced neurological deficits; modulated dopamine/GABA systems | 10mcg/kg | C — animal only |
| Wound healing (general) | Rat excision and incision models (animal study) | Faster closure; improved tensile strength; increased collagen deposition | 10mcg/kg | C — animal only |
| Anti-inflammatory | Multiple rat inflammation models (animal study) | Reduced inflammatory markers; modulated cytokine response | 10mcg/kg | C — animal only |
| Human trials | None completed | No data — no Phase 1, 2, or 3 trials as of 2026 | — | No human data |
Legal Status by Jurisdiction
| Jurisdiction | Status | Schedule | Notes |
|---|---|---|---|
| USA | Research chemical | None (DEA unscheduled) | FDA 503B compounding banned 2023; not a scheduled controlled substance; “not for human use” |
| UK | Not licensed | Not scheduled under Misuse of Drugs Act | No approved pharmaceutical product; importation for personal use is gray area |
| Australia | Prescription required | Schedule 4 | TGA Schedule 4; ASADA prohibited for athletes |
| Canada | Gray market | No DIN | No Health Canada approval; research chemical status |
| EU | Varies by country | No harmonized EU schedule | Generally unscheduled; no EMA-approved product |
The Honest Caveat
The depth of BPC-157 animal research is genuinely impressive — the Sikiric lab at the University of Zagreb has been systematically studying this peptide across multiple organ systems since 1994. These are not low-quality studies; they are published in peer-reviewed journals and represent a substantial body of mechanistic work.
But the translation from rat to human is not automatic. Numerous compounds with excellent animal data have failed in human trials — either because the mechanism does not translate, because dosing differs substantially, or because human biology is more complex. The absence of human trials for BPC-157 is not a technicality; it is a real and significant evidence gap.
Users who proceed with BPC-157 use should understand they are acting on animal data extrapolated to humans — reasonable given the preclinical profile, but unvalidated. The community-used doses of 200-400mcg per injection are approximations derived from rat studies, not clinically established human doses.
Related Pages
Sources
- Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract and wound healing. Molecules. 2022;27(18):6039. PMID 36144773
- Pevec D et al. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010;16(3):BR81-8. PMID 20190680
- Sikiric P et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2018;24(18):1990-2001. PMID 29663863
Frequently Asked Questions
Is BPC-157 a hormone?
No. BPC-157 does not bind the androgen receptor, the GH receptor, or any known hormone receptor. It is not a steroid, not a growth hormone secretagogue, and does not directly manipulate hormonal axes. Its mechanisms — NO synthase activation, VEGF upregulation, growth factor receptor modulation — are distinct from hormone-based performance compounds. This is relevant to its legal status: it is unscheduled precisely because it is not a controlled hormone analog.
How much of the BPC-157 evidence is from rats?
Essentially all of it. The Sikiric laboratory at the University of Zagreb has published extensively on BPC-157 in rat models since the mid-1990s, producing dozens of papers on wound healing, tendon repair, gut healing, and neuroprotection. These are genuine, peer-reviewed studies. However, no Phase 1, 2, or 3 human clinical trials have been completed as of 2026. The gap between extensive animal data and zero human trials is the defining characteristic of BPC-157's evidence situation.
What does 10mcg/kg in rats translate to in humans?
Using simple body-weight scaling, 10mcg/kg in a rat gives approximately 162mcg for a 70kg human. However, interspecies dose translation is imprecise — allometric scaling (which accounts for metabolic rate differences) would give a different number, and neither method has been validated for BPC-157 in humans. The 200-400mcg dosing commonly referenced in the research community is an approximation, not a clinically validated human dose.